Advanced Medicine Partners
Joseph Thai is an accomplished Senior Principal Engineer currently at Advanced Medicine Partners since January 2024, with previous roles at Jaguar Gene Therapy and Novartis Gene Therapies, where expertise in manufacturing science and technology was developed. Joseph Thai has a solid foundation in gene therapy operations from experience at Pfizer and has significant experience in manufacturing support and downstream operations at Seqirus. Competence in current Good Manufacturing Practice (cGMP) and good documentation practice (GDP) is evident through completion of document revisions and handling of deviation reports, CAPAs, and change controls. Joseph Thai also served as President of the Society of Asian Scientists and Engineers at North Carolina State University, promoting the success of Asian heritage scientists and engineers, and was an Undergraduate Research Assistant in the NCSU Environmental Engineering Lab, focusing on water quality testing. Joseph Thai holds a Bachelor’s Degree in Chemical Engineering with a biomanufacturing concentration from North Carolina State University.
Advanced Medicine Partners
Advanced Medicine Partners’ aims to set a new standard for manufacturing and testing innovative medicines that can potentially transform the lives of patients and families. The company delivers process development, manufacturing, analytical development and testing for advanced therapy products, including gene therapies. The company has the experience and capabilities to work with multiple platforms and modalities, including adeno-associated virus (AAV), lentivirus and other delivery systems. Advanced Medicine Partners leverages one of the most experienced genetic medicines teams – at all levels, from bench to boardroom – in the industry, and its exclusive manufacturing platform consistently produces yields that are among the highest in the industry and purity profiles that push the boundaries of what’s possible. The company’s proprietary adeno-associated virus (AAV) manufacturing process minimizes process and product-related impurities and consistently generates industry-leading functional full capsid ratios and best-in-class yields. This manufacturing process prioritizes patient safety while reducing cost of goods and will strive to set the standard for what regulatory agencies expect and patients deserve. Advanced Medicine Partners brings extensive operational experience from Jaguar Gene Therapy and other biotechnology companies. The Advanced Medicine Partners team has manufactured upwards of 350 total non-GMP batches and supplied over 20 preclinical studies, including initial new drug application (IND) enabling efficacy and good laboratory practice (GLP) toxicology studies. The company distinguishes itself from CDMOs by its partnership philosophy. Traditionally, CDMO operations work independently of their clients. Advanced Medicine Partners changes that dynamic by acting as a client’s extended workbench, removing CMC activities from the critical path, and offering real-time data to help clients drive decisions and accelerate their programs.